currently radionuclides used exclusively clinic clinical radioimmunotherapy studies main advantage relatively long path length biological tissue mm range sufficient irradiate cancer cells bound radiolabelled antibody effect alleviates problems inadequate uptake heterogeneous distribution radiolabelled antibodies tumours provide relatively uniform radiation dose tumour generally accepted class radionuclides appropriate radioimmunotherapy solid tumours large tumour burdens NUMBER cm alphaemitters mm range auger radionuclides majority electrons traverse nm shown efficient inducing lethal lesions single cells suggested classes radionuclides potential provide favourable therapeutic index radioimmunotherapy single tumour cells circulation micrometastases certain cases minimal residual disease aim article discuss different classes radionuclides potential clinical use radioimmunotherapy references NUMBER beta emitting beta emitters cross beta emitters shorter range NUMBER NUMBER ultra short electron emitting beta emitters beta emitters